Stanford University
Showing 181-200 of 656 Results
-
Michael Gensheimer
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Current Research and Scholarly InterestsIn addition to my clinical research in head and neck and lung cancer, I work on the application of computer science and machine learning to cancer research. I develop tools for analyzing large datasets to improve outcomes and safety of cancer treatment. I developed a machine learning prognostic model using data from around 13,000 patients with metastatic cancer which performs better than traditional models and physicians [PubMed ID 33313792]. We recently completed a prospective randomized study in thousands of patients in which the model was used to help improve advance care planning conversations.
I also work on the methods underpinning observational and predictive modeling research. My open source nnet-survival software that allows use of neural networks for survival modeling has been used by researchers internationally. In collaboration with the Stanford Research Informatics Center, I examined how electronic medical record (EMR) survival outcome data compares to gold-standard data from a cancer registry [PubMed ID 35802836]. The EMR data captured less than 50% of deaths, a finding that affects many studies being published that use EMR outcomes data. -
Andrew Gentles
Assistant Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsComputational systems biology
-
Heather Gentner
Director of Finance and Administration (SoM), Stem Cell Bio Regenerative Med Institute
Current Role at StanfordI am the Director of Finance and Administration for the Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM) in the School of Medicine. I oversee and carry out administrative and financial related functions for the department.
-
Paul George, MD, PhD
Associate Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsCONDUCTIVE POLYMER SCAFFOLDS FOR STEM CELL-ENHANCED STROKE RECOVERY:
We focus on developing conductive polymers for stem cell applications. We have created a microfabricated, polymeric system that can continuously interact with its biological environment. This interactive polymer platform allows modifications of the recovery environment to determine essential repair mechanisms. Recent work studies the effect of electrical stimulation on neural stem cells seeded on the conductive scaffold and the pathways by which it enhances stroke recovery Further understanding the combined effect of electrical stimulation and stem cells in augmenting neural repair for clinical translational is a major focus of this research going forward.
BIOPOLYMER SYSTEMS FOR NEURAL RECOVERY AND STEM CELL MODULATION:
The George lab develops biomaterials to improve neural recovery in the peripheral and central nervous systems. By controlled release of drugs and molecules through biomaterials we can study the temporal effect of these neurotrophic factors on neural recovery and engineer drug delivery systems to enhance regenerative effects. By identifying the critical mechanisms for stroke and neural recovery, we are able to develop polymeric technologies for clinical translation in nerve regeneration and stroke recovery. Recent work utilizing these novel conductive polymers to differentiate stem cells for therapeutic and drug discovery applications.
APPLYING ENGINEERING TECHNIQUES TO DETERMINE BIOMARKERS FOR STROKE DIAGNOSTICS:
The ability to create diagnostic assays and techniques enables us to understand biological systems more completely and improve clinical management. Previous work utilized mass spectroscopy proteomics to find a simple serum biomarker for TIAs (a warning sign of stroke). Our study discovered a novel candidate marker, platelet basic protein. Current studies are underway to identify further candidate biomarkers using transcriptome analysis. More accurate diagnosis will allow for aggressive therapies to prevent subsequent strokes. -
Marios Georgiadis
Instructor, Radiology
BioMarios is an Instructor of Neuroimaging, part of the Faculty of the Stanford University School of Medicine.
He is in the Translational Neuroimaging lab, headed by Dr Michael Zeineh, since 2019.
His research focuses mainly on myelin and iron imaging in neurologic diseases, primarily using experimental X-ray and MRI approaches. He is also actively involved in projects related to imaging and modeling brain trauma, exosome signatures of neurodegeneration, and imaging the brain using advanced forms of electron and light microscopy.
Marios is a mechanical engineer by training (School of Mechanical Engineering, National Technical University of Athens, Greece). His thesis "Closed-loop force control of a haptic surgical simulator", was performed in the Control Systems Lab of Prof. Evangelos Papadopoulos.
In 2011 he obtained his MSc in Biomedical Engineering from ETH Zurich (Swiss Federal Institute of Technology). He performed his thesis in IBM Research on "Advanced pathology using the Microfluidic Probe", under Emmanuel Delamarche and Govind Kaigala, and was awarded the ETH medal for this work.
He completed his PhD in Bone Biomechanics in the lab of Prof. Ralph Muller in ETH Zurich, where he developed X-ray scattering-based methods to investigate bone microstructure in 3D, research that earned him the 2nd Student Award from the European Society for Biomechanics in 2015.
In 2016 he started using imaging methods to study brain microstructure, in the lab of Prof. Markus Rudin, in the Institute for Biomedical Engineering of ETH Zurich. There, he combined X-ray scattering with DTI, histology and CLARITY for studying rodent brain.
In 2017 he joined the MRI Biophysics group of Profs. Els Fieremans and Dmitry Novikov in New York University School of Medicine, to study human and mouse brain microstructure using X-ray scattering and diffusion MRI.
His research on myelin in mouse and human brain using X-ray scattering has been supported twice by the Swiss National Science Foundation. -
Daniel Aaron Gerber, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Gerber is a critical care cardiologist and co-director of Stanford's Cardiac ICU. He has dual subspecialty training in cardiovascular and critical care medicine and additional board certification in echocardiography. He completed his residency in internal medicine, fellowship in cardiovascular medicine, and an additional fellowship in critical care medicine at Stanford University and joined as faculty in 2021 as a Clinical Assistant Professor in the Department of Medicine’s Division of Cardiovascular Medicine.
Dr. Gerber manages the full spectrum of heart and vascular conditions with a focus on critically ill patients with life-threatening cardiovascular disease. He is active in medical education, teaching introductory echocardiography to Stanford medical students and residents, co-directing the Stanford Critical Care Medicine Critical Care Ultrasound Program, and lecturing nationally on critical care echocardiography and point-of-care ultrasonography at the Society of Critical Care Medicine’s annual congress. Finally, Dr. Gerber’s research interests focus on optimizing cardiac intensive care, including working with the Critical Care Cardiology Trials Network (CCCTN) - a national network of tertiary cardiac ICUs coordinated by the TIMI Study Group - and studying acute mechanical circulatory support techniques to improve patient outcomes and care processes. -
Yael Gernez
Clinical Associate Professor, Pediatrics - Immunology and Allergy
BioMy clinic focuses on solving the molecular puzzles that underlie rare allergic and immunologic diseases to shed light on fundamental principles governing allergy, inflammation and immune system defects. My goal is to find better and safer therapies for my patients with rare diseases that include autoinflammation, autoimmunity and primary immune deficiency. It is important to highlight that every patient requires individualized therapeutic approaches based on their underlying genetic problem and the types and severity of their clinical manifestations. For some patients, a hematopoietic stem cell transplant (HSCT) is curative while for others, a targeted drug therapy, such as a biologic or small molecule agent, is most suitable. In some cases, a truly novel therapy may be required, .e.g., anti-sense oligonucleotide therapy to suppress aberrant gene splicing or adoptive cellular therapy. My passion is to provide the best personalized therapy for our patients with allergy and immunology diseases. This often requires performing very specialized functional assays and in some cases in enlisting laboratories with specific expertise or interest in particular genetic disorders.
-
Rabin Gerrah
Clinical Assistant Professor, Cardiothoracic Surgery
BioDr. Rabin Gerrah is a cardiothoracic surgeon and specializes in surgical treatment of heart diseases such as ischemic, valvular, structural and congenital heart diseases. He has been trained at Harvard University and Columbia University Hospitals. Dr. Gerrah has been involved in multiple medical research projects and has patented and developed innovative surgical devices and technologies.
-
Elias Roth Gerrick
Basic Life Research Scientist, Pathology Sponsored Projects
BioEli received his B.S. in Microbiology and Immunology from U.C. Irvine in 2013, where he worked in the lab of Dr. Celia Goulding. He earned his Ph.D. from Harvard University in 2018 in the lab of Dr. Sarah Fortune, where he studied post-transcriptional regulation of gene expression in Mycobacterium tuberculosis. Eli joined the Howitt lab at Stanford in the summer of 2018, where he is studying the influence of protozoan members of the microbiome on intestinal immunity.
